Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Portfolio Pulse from
Olema Pharmaceuticals has entered into a supply agreement with Novartis for KISQALI, supporting its upcoming phase 3 OPERA-02 study for ER+/HER2- metastatic breast cancer. The study is set to begin in mid-2025, with data from another ongoing study expected in 2026.
December 02, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novartis has entered into a supply agreement with Olema Pharmaceuticals to provide KISQALI for a phase 3 study targeting breast cancer, starting mid-2025.
While the agreement with Olema highlights Novartis's role in supporting cancer research, it is a small part of its broader operations, thus having a neutral short-term impact on its stock.
CONFIDENCE 85
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Olema Pharmaceuticals has secured a supply agreement with Novartis for KISQALI, which will be used in its upcoming phase 3 OPERA-02 study for breast cancer, starting mid-2025.
The agreement with Novartis provides Olema with a critical component for its upcoming study, potentially enhancing its research capabilities and future market position in the breast cancer treatment space.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90